Insight Molecular Diagnostics Inc.
IMDX
$4.01
$0.174.43%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -53.86% | -98.50% | -23.35% | 126.09% | 398.08% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -53.86% | -98.50% | -23.35% | 126.09% | 398.08% |
| Cost of Revenue | -54.44% | -97.91% | -26.01% | 181.40% | 462.50% |
| Gross Profit | -53.55% | -98.87% | -19.61% | 93.06% | 369.44% |
| SG&A Expenses | 16.61% | 24.81% | 22.76% | 8.95% | 25.98% |
| Depreciation & Amortization | -- | -- | -100.00% | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.84% | 28.61% | 222.20% | 22.19% | 31.02% |
| Operating Income | -29.55% | -74.51% | -268.49% | -20.31% | -24.28% |
| Income Before Tax | -15.58% | 35.69% | 31.50% | 19.56% | -115.06% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -15.58% | 35.69% | 31.50% | 19.56% | -115.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.58% | 35.69% | 31.50% | 19.56% | -115.06% |
| EBIT | -29.55% | -74.51% | -268.49% | -20.31% | -24.28% |
| EBITDA | -30.47% | -78.67% | -288.00% | -17.42% | -21.40% |
| EPS Basic | -0.72% | 52.12% | 62.87% | 65.57% | 14.65% |
| Normalized Basic EPS | -12.78% | -31.16% | 3.25% | 49.60% | 49.87% |
| EPS Diluted | -0.72% | 52.12% | 62.87% | 65.57% | 14.65% |
| Normalized Diluted EPS | -12.78% | -31.16% | 3.25% | 49.60% | 49.87% |
| Average Basic Shares Outstanding | 14.76% | 34.35% | 84.47% | 133.58% | 148.82% |
| Average Diluted Shares Outstanding | 14.76% | 34.35% | 84.47% | 133.58% | 148.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |